AddThis Feed Button "Frequently Copied, Never Duplicated"

Thursday, November 20, 2008

Gingko Study Leaves Much to Be Considered

It is interesting to note that Schwabe supplied the gingko tablets for this study. As a pharmaceutical company it has had a financial interest in the Nature's Way brand for some years. It is a German company that focuses on standardized herbal products because of the impact of Commission E and CODEX in that country.

This makes a major difference in the outcome of any study that looks at possible treatments for a disease condition. The low does rate of a 120 mg. tablet is also an issue; the dose may just be too low to achieve any benefit.

Most traditional herbalists would not suggest the use of a standardized product for starters, except in very specific situations. The push to standardized herbal products has come about in an effort to isolate certain factors, generally single elements, found in whole herb products that are thought to be the "effective ingredient". This makes them behave more like drugs rather than herbs.

Gingko can provide antioxidant protection, support normal memory function, promote mental clarity, maintain healthy eyes, support normal hearing function, support the body as it ages, help maintain proper energy, support a healthy cardiovascular system, support healthy blood function, support healthy oxygen flow to the brain and peripheral areas of the body.

Gingko or Gingko biloba as it is commonly known is a popular herb that comes from the gingko biloba tree found throughout the world. It is a herb which has been used for 5,000 years by humans, especially in Chinese or Oriental medicine. It is the most popular prescription drug in Germany and France for symptoms of aging in association with deteriorating memory. In 1988 it was prescribed more than 5 million times in Germany alone. Not only is it used for improved memory functions but it possesses properties which improve blood circulation.

Hundreds of scientific papers have been published on ginkgo, confirming that ginkgo stimulates blood flow to the brain by dilating blood vessels, decreasing platelet aggregation, and being a powerful antioxidant to block oxidation of the fatty cell membrane.

As a result, it improves cerebral vascular insufficiency, memory and peripheral circulation in conditions such as intermittent claudication.

Gingko is not recommended during pregnancy and lactation.

You may read more about gingko here.

In our work we prefer to utilize liquid herbal extracts and sometimes herbal capsules that are a combination of the complete extract and whole herb. We also custom blend combination formulas based on client needs. We also would not hang our hat on the results of this study by failing to offer gingko to people with Alzheimer's disease if the situtaion dictated it.

Referring to the "blood thinning" function of gingko, it may, like vitamin E and other natural products, be a safer alternative to aspirin and warfarin or drugs such as Plavix in the long term.

Ginkgo fails to prevent Alzheimer's in large studyBy CARLA K. JOHNSON, Associated Press Writer
Tue Nov 18, 2008

CHICAGO – The dietary supplement ginkgo, long promoted as an aid to memory, didn't help prevent dementia and Alzheimer's disease in the longest and largest test of the extract in older Americans. "We don't think it has a future as a powerful anti-dementia drug," said Dr. Steven DeKosky of the University of Virginia School of Medicine, who led the federally funded study.

Extracts from ginkgo tree leaves have antioxidant and anti-inflammatory effects, but earlier research on ginkgo and memory showed mixed results. Annual U.S. sales of the supplement reached $107 million in 2007, according to Nutrition Business Journal estimates.

For the new study, appearing in Wednesday's Journal of the American Medical Association, researchers recruited more than 3,000 people, ages 75 and older, from voter and mailing lists in Maryland, Pennsylvania, California and North Carolina.

Half were randomly assigned to take 120 milligrams of ginkgo biloba twice a day, a typical dose taken by people who think it may help memory. The others took identical dummy pills.

Participants were screened for dementia every six months. After six years, dementia had been diagnosed at a similar rate in both groups; 277 in the ginkgo group and 246 in the group taking the dummy tablets. When the researchers looked only at Alzheimer's disease, that rate too was similar.

At the start, some people showed mild difficulties with thinking; ginkgo didn't work to prevent dementia in those people either.

Ginkgo appears relatively safe, DeKosky said. There was no difference in the rate of adverse events such as heart attacks and gastrointestinal bleeding between the groups. There were 16 strokes from bleeding in the brain in the ginkgo group versus eight in the placebo group, a difference that wasn't statistically significant, he said, because the number of strokes was too small.

People on the blood thinner warfarin shouldn't take ginkgo because of the risk of increased bleeding.

Proponents claim ginkgo protects the brain by preventing the buildup of an Alzheimer's-related protein or by preventing cell-damaging oxidative stress.

Would ginkgo work better to prevent dementia if people started taking it earlier, say, in middle age? The study didn't look at that, DeKosky acknowledged, adding that following people for 25 years from middle age to old age would be expensive research. The study also didn't test whether ginkgo improves thinking and memory in the short term.

"It would have been terrific if this worked. It's inexpensive, available and relatively safe," said Paul Solomon, professor of neuroscience at Williams College in Williamstown, Mass., who wasn't involved in the new study but has studied ginkgo.

"Now with this kind of evidence, you can confidently tell people it didn't show benefit in more than 3,000 people in six years of research," Solomon said.

There may still be a role for ginkgo in treating, rather than preventing, Alzheimer's disease, said Michael McGuffin, president of the American Herbal Products Association, a trade association.

Some previous ginkgo trials have shown no benefit in Alzheimer's symptom treatment, while others have found it comparable to prescription drugs such as Aricept, also known as donepezil.

A four-month supply of ginkgo can cost less than $10. But not all brands contain what their labels claim., which tests the ingredients in supplements, reported Tuesday that of seven ginkgo products it reviewed, five failed to pass its tests. An eighth ginkgo product also passed the group's test in a voluntary certification program.

The dementia study was funded by a grant from the National Institutes of Health's National Center for Complementary and Alternative Medicine, which is undertaking large, scientific tests of a number of commonly used dietary supplements. The agency said it's the largest-ever randomized trial of a botanical medicine. There have been larger studies of vitamins and minerals.

DeKosky reported receiving grants from and acting as a consultant for several drug companies, including some that make dementia drugs. Schwabe Pharmaceuticals of Karlsruhe, Germany, provided the ginkgo tablets and identical placebos.

On the Net: JAMA:
Ginkgo fact sheet:
Copyright © 2008 The Associated Press.

No comments: